Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
How Has The GM1 Gangliosidosis Market Growth Evolved From 2024 To 2025, And What’s Ahead?
In recent times, there has been a quick upswing in the GM1 gangliosidosis market size. From 2024 to 2025, it is projected to rise from $0.51 billion to $0.57 billion with a CAGR of 11.4%. This significant increase during the historical period is due to a surge in the patient count suffering from GM1 gangliosidosis, an expanded focus in the GM1 gangliosidosis sector, a growing awareness of rare diseases, rising popularity of research centered around patients, and an amplifying emphasis on early intervention.
The market size of GM1 gangliosidosis is projected to undergo fast-paced growth in the coming years. By 2029, it is anticipated to reach $0.87 billion, at a compound annual growth rate (CAGR) of 11.1%. The proliferation in the forecast period is owed to a surge in GM1 gangliosidosis cases, an increased prevalence of lysosomal storage disorders, a rising count of clinical trials, an enhanced focus on gene therapy and editing, a growing emphasis on personalized and precision medicine, and an uptick in the acceptance of genetic screening programs. Notable trends in the projected period encompass advancements in gene-editing technologies, the incorporation of technology in healthcare, improvements in diagnostic methods, cutting-edge formulations, and progress in genetic therapies.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21194&type=smp
What Are the Primary Drivers Supporting the Market Growth of the GM1 Gangliosidosis Market?
The growth of the GM1 gangliosidosis market is expected to be propelled by the rising acceptance of gene therapy. Gene therapy, a medical procedure that modifies or substitutes genes in a person’s cells to cure or prevent diseases, is becoming increasingly popular. This growing acceptance is a result of progress in genetic research, improved results for conditions previously considered untreatable, and increasing regulatory endorsement for pioneering therapies. Gene therapy for GM1 gangliosidosis administers a functioning version of the faulty gene (GLB1) into patient cells to revitalize ß-galactosidase enzyme activity and decrease toxic substrate accretion. For example, in April 2024, as per the American Society of Gene & Cell Therapy, a US-base non-profit medical and scientific establishment, there was a 10% increase in the number of phase III gene therapy clinical trials in the fourth quarter. This was the premier quarterly increase since the third quarter of 2022. Consequently, the booming acceptance of gene therapy propels the GM1 gangliosidosis market’s growth.
Which Primary Segments of the GM1 Gangliosidosis Market Are Driving Growth and Industry Transformations?
The GM1 gangliosidosis market covered in this report is segmented –
1) By Disease Type: Type 1 GM1 Gangliosidosis, Type 2 GMT Gangliosidosis, Type 3 GMT Gangliosidosis
2) By Treatment: Anticonvulsants, Bone Marrow Transplantation, Cord-Blood Hematopoietic Stem-Cell Transplantation, Enzyme Replacement, Gene Therapy
3) By End-User: Research Institutes, Hospitals, Other End-Users
Subsegments:
1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset, Atypical Infantile Onset
2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset, Atypical Juvenile Onset
3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset, Atypical Adult Onset
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21194&type=smp
Which Regions Are Key Players in the Growth of the What Are the Primary Drivers Supporting the Market Growth of the GM1 Gangliosidosis Market? Market?
North America was the largest region in the GM1 gangliosidosis market in 2024. The regions covered in the GM1 gangliosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Most Significant Market Trends in the GM1 Gangliosidosis Market?
Key players in the GM1 gangliosidosis market are strengthening their market stand by focusing on strategic alliances. These partnerships are pivotal in propelling the progress of gene therapy by uniting experience, resources and cutting-edge technology to expedite research, clinical assessments and product distribution. As an illustration, GEMMA Biotherapeutics Inc., a biotechnology firm based in the U.S., formed a partnership with Oswaldo Cruz Foundation (Fiocruz), a Brazil-based medical research establishment, to create gene treatments for uncommon diseases, including GM1 gangliosidosis, in October 2024. The deal encompasses up to $100 million that Fiocruz will provide for clinical studies and production, with a goal to facilitate the availability of these complex therapies through Brazil’s government-run healthcare system. The partnership is centered around technology exchange and strives to make treatments, formerly available only to higher-income groups, accessible to all.
View the full report here:
https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report
What Parameters Are Used to Define the GM1 Gangliosidosis Market?
GM1 gangliosidosis is a rare, inherited neurodegenerative disorder caused by a deficiency of the ß-galactosidase (GLB1) enzyme, leading to toxic accumulation of GM1 gangliosides in the brain and other tissues. It results in progressive neurological decline, developmental delays, muscle weakness, and organ enlargement.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21194
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model